Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ).
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced that its board of directors will convene on March 28, 2025, to approve the annual results for the year ending December 31, 2024, and to consider recommending a final dividend. This meeting is significant as it will determine the company’s financial performance for the past year and potentially impact shareholder returns through dividend announcements.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the production and distribution of heparin products. The company operates within the pharmaceutical industry and focuses on providing essential medical products to both domestic and international markets.
YTD Price Performance: 10.86%
Average Trading Volume: 2,754,797
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$15.67B
For a thorough assessment of 9989 stock, go to TipRanks’ Stock Analysis page.